Akeso lung cancer drug improved survival, challenging standard treatment
Source: SeekingAlpha
2026-05-31 12:21:07 ET
More on Akeso
- Summit Therapeutics falls after update on Akeso-partnered lung cancer trial
- Historical earnings data for Akeso
- Financial information for Akeso
Read the full article on Seeking Alpha
For further details see:
Akeso lung cancer drug improved survival, challenging standard treatment
Akeso
NASDAQ: AKESF
AKESF Trading
-6.92% G/L:
$12.10 Last:
2,287 Volume:
$12.174 Open:
